Evidence map›Paper›PMID 36765708›Full record

ArticleCancers2023

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study.

Ivan Guerra, Luis Bujanda, Miriam Mañosa, Isabel Pérez-Martínez, María José Casanova, Luisa de la Peña, Marina de Benito, Montserrat Rivero, Pilar Varela, Lorena Bernal and 18 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Ivan GuerraGastroenterology Unit, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.
Luis BujandaGastroenterology Unit, Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco UPV/EHU, 20014 Donostia-San Sebastián, Spain.
Miriam MañosaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.
Isabel Pérez-MartínezGastroenterology Unit, Hospital Universitario Central de Asturias, and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
María José CasanovaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.
Luisa de la PeñaGastroenterology Unit, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, l'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-8496-3415
Marina de BenitoGastroenterology Unit, Hospital Universitario Río Hortega, 47012 Valladolid, Spain.ORCID 0000-0002-6345-016X
Montserrat RiveroGastroenterology Unit, Hospital Universitario Marqués de Valdecilla and IDIVAL, 39008 Santander, Spain.
Pilar VarelaGastroenterology Unit, Hospital Universitario de Cabueñes, 33394 Gijón, Spain.ORCID 0000-0003-1737-3236
Lorena BernalCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.
Ana Carolina FrancoOnco-Hematology Unit, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.
Yolanda BerGastroenterology Unit, Hospital General San Jorge, 22004 Huesca, Spain.ORCID 0000-0002-5184-8349
Marta PiquerasGastroenterology Unit, Consorci Sanitari Terrassa, 082217 Terrassa, Spain.ORCID 0000-0002-3874-2638
Carlos TardilloGastroenterology Unit, Hospital Universitario Nuestra Señora de la Candelaria, 38010 Tenerife, Spain.
Ángel PonferradaGastroenterology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.ORCID 0000-0002-1176-276X
Sonsoles OlivaresGastroenterology Unit, Hospital 12 de Octubre, 28041 Madrid, Spain.
Alfredo J LucendoCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.ORCID 0000-0003-1183-1072
Pau GilabertGastroenterology Unit, Hospital de Viladecans, 08840 Barcelona, Spain.
Mónica Sierra AusínGastroenterology Unit, Complejo Asistencial Universitario de León, 24071 León, Spain.ORCID 0000-0003-3342-8209
María BellartGastroenterology Unit, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.
Amaia HerrarteGastroenterology Unit, Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco UPV/EHU, 20014 Donostia-San Sebastián, Spain.
Margalida CalafatCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.ORCID 0000-0003-2335-3792
Ruth de FranciscoGastroenterology Unit, Hospital Universitario Central de Asturias, and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Javier P GisbertCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.ORCID 0000-0003-2090-3445
Jordi GuardiolaGastroenterology Unit, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, l'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-0464-241X
Eugeni DomènechCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.ORCID 0000-0002-2315-7196
Fernando BermejoGastroenterology Unit, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain.
ENEIDA project of GETECCU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD; 95% CI 1.8-3.1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 ± 17 years old) and anti-TNF drugs (47 ± 17) than in those patients not treated with these drugs (63 ± 12;

Indexed as

anti-TNFinflammatory bowel diseaselymphomathiopurines

Identifiers

PMID36765708
PMCPMC9913166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.